Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate
Loading...
Date
Authors
Tsoumani, M. E.
Kalantzi, K. I.
Dimitriou, A. A.
Ntalas, I. V.
Goudevenos, I. A.
Tselepis, A. D.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer reviewed
Educational material type
Conference Name
Journal name
Expert Opinion on Pharmacotherapy
Book name
Book series
Book edition
Alternative title / Subtitle
Description
Objective: The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. In this study we compared the antiplatelet effectiveness of a generic clopidogrel salt, clopidogrel besylate (CB), with the original CHS in patients with an ACS. Research design and methods: Ninety-six ACS patients were randomized to receive a 600-mg loading dose of either CHS (n = 45) or CB (n = 51), followed by 75 mg/day. Sixty-eight patients underwent a percutaneous coronary intervention (PCI), whereas 28 were treated conservatively. Platelet aggregatory response, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, P-selectin expression and platelet-leucocyte conjugates were determined before clopidogrel loading (baseline), as well as at 5 days and at 1 month afterwards. Results: No difference in the clopidogrel response variability was observed between patients receiving CHS or CB either at 5 days or at 1 month of follow-up. Similarly, no difference in the inhibition of platelet aggregation, P-selectin expression or in the platelet-leucocyte conjugates was observed between CHS and CB group during the follow-up. Conclusions: There is no overall significant difference in the antiplatelet efficacy between CB and CHS during their administration in ACS patients for up to 1 month after the episode.
Description
Keywords
acute coronary syndromes, clopidogrel, percutaneous coronary intervention, platelets, stimulated phosphoprotein phosphorylation, st-segment elevation, antiplatelet therapy, stent thrombosis, activation, atherothrombosis, atherosclerosis, intervention, inflammation, disease
Subject classification
Citation
Link
<Go to ISI>://000299091900001
http://informahealthcare.com/doi/abs/10.1517/14656566.2012.644536
http://informahealthcare.com/doi/abs/10.1517/14656566.2012.644536
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας